PURPLE BIOTECH LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.3 ILa | +5.97% |
|
+9.79% | -33.23% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.23% | 14.83M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- PPBT Stock
- News Purple Biotech Ltd
- Purple Biotech : Commences Phase 1b/2 Clinical Trial of CM24 in Multiple Advanced Cancers
